Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2009 Aug;63(8):1198-204.
doi: 10.1111/j.1742-1241.2009.02108.x.

Tolterodine extended release is well tolerated in older subjects

T L Griebling  1 , S R Kraus, H E Richter, D B Glasser, M Carlsson
Affiliations
Free PMC article
Meta-Analysis

Tolterodine extended release is well tolerated in older subjects

T L Griebling et al. Int J Clin Pract. 2009 Aug.
Free PMC article

Abstract

Objectives: To investigate the tolerability of tolterodine extended release (ER) in older subjects with overactive bladder (OAB).

Methods: This was a retrospective analysis of pooled data from five large, randomised, double-blind, placebo-controlled trials. Subjects with OAB symptoms, including urinary frequency and urgency (and nocturia in two studies) with or without urgency urinary incontinence, received qd treatment with tolterodine ER (4 mg) or placebo for 8-12 weeks. Data were stratified post hoc by age group: < 65 (n = 2531), 65-74 (n = 1059) and > or = 75 years (n = 573). Tolerability was assessed by evaluating the occurrence of adverse events (AEs). AE occurrences from each study were mapped to the MedDRA coding dictionary of preferred terms.

Results: Discontinuation rates were slightly higher among subjects > or = 75 years of age vs. those < 65 years of age; however, this was observed in subjects treated with placebo as well as tolterodine ER. Overall, there were no significant differences in the occurrence of dry mouth, headache, constipation, nausea, urinary tract infection, blurred vision, dry eye, dizziness and micturition disorder in older (65-74 or > or = 75 years) vs. younger (< 65 years) subjects treated with tolterodine ER relative to placebo (treatment x age; all p > 0.1). Dry mouth was the only AE consistently associated with tolterodine ER treatment (< 65 years, 17%; 65-74 years, 16%; > or = 75 years, 15%). The occurrence of all other AEs was < or = 5% in most age and treatment cohorts. Most AEs were mild or moderate in all age and treatment cohorts.

Conclusion: The nature and frequency of AEs associated with tolterodine ER treatment were similar across age groups in subjects with OAB, suggesting that tolterodine ER was not associated with an increased risk of AEs in older vs. younger subjects and, thus, is a suitable first-line pharmacotherapy treatment for OAB in this population.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Occurrence of dry mouth (A), constipation (B), headache (C), nausea (D), urinary tract infection (E), blurred vision (F), dry eye (G), dizziness (H) and micturition disorder (I) by treatment and age group. TOL ER, tolterodine extended release
See this image and copyright information in PMC

References

    1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49. - PubMed
    1. Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn. 2006;25:293. - PubMed
    1. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–36. - PubMed
    1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–6. - PubMed
    1. Federal Interagency Forum on Aging-Related Statistics . Older Americans 2004: Key Indicators of Well-Being. Washington DC: Federal Interagency Forum on Aging-Related Statistics; 2004.

Publication types

MeSH terms